NYSE · TEVA
Teva Pharmaceutical Industries Limited
$41.47+$1.50 (+3.75%)
Teva Pharmaceutical Industries Limited’s quoted price sits in the upper half of its reported 52-week range, 1.31% below the high.
Loading market information…
NYSE · RDY · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Dr. Reddy's Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 9.96% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Dr. Reddy's Laboratories Limited’s forward annual dividend is $0.08 per share, paid annual. The forward yield is 0.59% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Dr. Reddy's Laboratories Limited’s next earnings report is currently expected on Jan 22, 2027, with estimated earnings per share of $0.15. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Dr. Reddy's Laboratories Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisions. The Global Generics segment is responsible for the manufacturing and sale of both prescription and over-the-counter finished pharmaceutical products. These offerings are available either under a proprietary brand or as generic formulations that are therapeutically identical to their branded equivalents. This segment also includes the company's biologics ventures. The Pharmaceutical Services and Active Ingredients (PSAI) division focuses on producing and distributing active pharmaceutical ingredients (APIs) and chemical intermediates, which serve as crucial building blocks for final drug products. Additionally, PSAI provides contract research services and produces custom-specified APIs and steroids for clients. The Proprietary Products segment is dedicated to the research and advancement of unique pharmaceutical formulations. The Others segment is actively involved in developing treatments, primarily for oncology (cancer) and inflammatory conditions. Dr. Reddy's addresses a broad spectrum of therapeutic areas, including gastrointestinal issues, cardiovascular health, diabetes, dermatological concerns, cancer, respiratory diseases, oral health, urological disorders, and nephrological conditions. The company has also established a partnership with Curis, Inc., centered on the discovery, development, and commercialization of small molecule antagonists designed for immuno-oncology and precision oncology targets. Founded in 1984, Dr. Reddy's Laboratories Limited maintains its principal office in Hyderabad, India.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:32 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2026 | Jul 23, 2025 | $0.20+11.11% vs estimate | $988.91M-2.56% vs estimate |
|---|
| Q4 2025 | May 9, 2025 | $0.22+10.0% vs estimate | $996.16M+1.84% vs estimate |
|---|
| Q3 2025 | Jan 29, 2025 | $0.20+5.26% vs estimate | $969.62M-0.62% vs estimate |
|---|
THE ANALYST VIEW
12 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $14.35.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$41.47+$1.50 (+3.75%)
Teva Pharmaceutical Industries Limited’s quoted price sits in the upper half of its reported 52-week range, 1.31% below the high.
₹1,761.00+₹3.50 (+0.2%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 13.97% below the high.
$8.57-$1.43 (-14.3%)
Haleon plc’s quoted price sits in the lower half of its reported 52-week range, 24.02% below the high.
$19.20+$0.43 (+2.29%)
Viatris Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.13% below the high.
₹1,358.00-₹7.60 (-0.56%)
Cipla Limited’s quoted price sits in the lower half of its reported 52-week range, 14.77% below the high.
₹2,469.30-₹20.70 (-0.83%)
Mankind Pharma Limited’s quoted price sits in the upper half of its reported 52-week range, 6.54% below the high.
$21.35+$0.21 (+0.99%)
Amneal Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.52% below the high.
$8.91+$1.99 (+28.76%)
Bausch Health Companies Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.44% below the high.
